Actively Recruiting
Safety Study of RSV Preventive Monoclonal Antibody Given With Routine Childhood Vaccines in Infants Aged 6 to Under 30 Weeks
Led by Duke University · Updated on 2026-03-16
524
Participants Needed
6
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of giving a respiratory syncytial virus RSV preventive monoclonal antibody along with routine childhood vaccines at the same visit compared to giving them at separate visits. This randomized, open-label trial focuses on infants aged 6 to under 30 weeks and aims to understand any differences in fever and other adverse events after immunizations. Participants will be randomly assigned to one of two groups one group receives the RSV preventive monoclonal antibody together with routine vaccines at the first visit, while the other group receives the routine vaccines first and the RSV antibody at a second visit. Parents or guardians will monitor and record fever and other side effects for seven days after each vaccination using a web-based system or paper diary. Serious adverse events will be tracked throughout the study. During the study, parents or guardians will report symptoms daily for a week after each visit. Researchers will collect and review medical information as needed and evaluate the number of participants who develop fever, including moderate to severe fever, and any serious or special adverse events. The study includes follow-up for up to 98 days after immunization to ensure safety. The total duration and specific visit schedules support careful monitoring of the infants responses to the vaccines.
CONDITIONS
Brief Title
Safety of RSV Preventive Monoclonal Antibody
Research Team
M
Michael J Smith, MD
E
Emily A Randolph, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here